Massachusetts is investigating high cost of hepatitis C drug

Massachusetts is investigating high cost of hepatitis C drug


The Massachusetts attorney general's office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high. Attorney General Maura Healey on Wednesday released a letter sent to the chief executive of California-based Gilead Sciences Inc. In it, Healey said her office was examining whether the pricing constituted an unfair trade practice.



from Biotech News